TY - JOUR
T1 - Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence
AU - Shoptaw, Steve
AU - Heinzerling, Keith G.
AU - Rotheram-Fuller, Erin
AU - Kao, Uyen H.
AU - Wang, Pin Chieh
AU - Bholat, Michelle A.
AU - Ling, Walter
N1 - Funding Information:
Bholat are affiliated with UCLA Department of Family Medicine, Los Angeles, CA. Walter Ling is affiliated with UCLA Integrated Substance Abuse Programs, Los Angeles, CA. Address correspondence to: Steve Shoptaw, PhD, David Geffen School of Medicine at UCLA, Department of Family Medicine, 10880 Wilshire Boulevard, Suite 540, Los Angeles, CA 90095 (E-mail: sshoptaw@mednet.ucla.edu). The authors gratefully acknowledge support by NIDA grant P50 DA 12755.
PY - 2008/2/27
Y1 - 2008/2/27
N2 - Bupropion hydrochloride is a dopamine and norepinephrine reuptake inhibitor which may be an effective treatment for cocaine dependence due to its ability to reverse deficits in dopaminergic functioning that occur in chronic cocaine users. We performed a randomized, double-blind, placebo controlled trial comparing outpatient treatment with bupropion (N = 37) and placebo (N = 33) in combination with standard cognitive behavioral therapy. There were no statistically significant differences between bupropion and placebo in treatment outcomes, including aggregate measures of urine drug screen results (Joint Probability Index at 16 weeks: 0.43 for bupropion and 0.38 for placebo), treatment retention, cocaine craving ratings, and assessments of depressive symptoms. The failure to find an effect for bupropion relative to placebo, when combined with standard cognitive behavioral therapy, dampens enthusiasm for future development of bupropion as a cocaine pharmacotherapy.
AB - Bupropion hydrochloride is a dopamine and norepinephrine reuptake inhibitor which may be an effective treatment for cocaine dependence due to its ability to reverse deficits in dopaminergic functioning that occur in chronic cocaine users. We performed a randomized, double-blind, placebo controlled trial comparing outpatient treatment with bupropion (N = 37) and placebo (N = 33) in combination with standard cognitive behavioral therapy. There were no statistically significant differences between bupropion and placebo in treatment outcomes, including aggregate measures of urine drug screen results (Joint Probability Index at 16 weeks: 0.43 for bupropion and 0.38 for placebo), treatment retention, cocaine craving ratings, and assessments of depressive symptoms. The failure to find an effect for bupropion relative to placebo, when combined with standard cognitive behavioral therapy, dampens enthusiasm for future development of bupropion as a cocaine pharmacotherapy.
KW - Bupropion hydrochloride
KW - Cocaine dependence
KW - Randomized controlled trial
KW - Zyban
UR - http://www.scopus.com/inward/record.url?scp=46449103898&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=46449103898&partnerID=8YFLogxK
U2 - 10.1300/J069v27n01_02
DO - 10.1300/J069v27n01_02
M3 - Article
C2 - 18551884
AN - SCOPUS:46449103898
SN - 1055-0887
VL - 27
SP - 13
EP - 23
JO - Journal of Addictive Diseases
JF - Journal of Addictive Diseases
IS - 1
ER -